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ORIGINAL ARTICLEComparison of Binax NOW urine antigen test and pneumococcal DNA
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MalawiAbstractDiagnosis of invasive pneumococcal disease is challenging. We compared Binax NOW pneumococcal urinary antigen test with blood
pneumococcal PCR in healthy Malawian children with and without pneumococcal carriage, and we found a high false-positive rate with
Binax NOW. Blood pneumococcal PCR positivity was 66/88 (75%) compared to 5/27 (18%) when nasopharyngeal swabbing was
performed ﬁrst compared to after blood sampling for pneumococcal blood PCR. We speculate that nasopharyngeal swabbing may be
causing a breach of mucosal integrity, leading to invasion into the bloodstream. These ﬁndings need to be conﬁrmed with autolysin-based
PCR assays.
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both should be considered ﬁrst author.IntroductionInvasive pneumococcal disease (IPD) is a major contributor to
mortality in the developing world, especially in the context of
HIV [1]. The diagnosis of IPD is problematic, particularly for
pneumococcal pneumonia, because of a low rate of culture-
positive patients, suggesting that the true disease burden is
likely to be underestimated. Equally, the distinction betweenw Microbe and New Infect 2015; 8: 4–6
w Microbes and New Infections © 2015 The Authors. Published by Elsevier Ltd on behalf of
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p://dx.doi.org/10.1016/j.nmni.2015.08.001nasopharyngeal carriage and IPD is an important one for children
in sub-Saharan Africa in order to reliably quantify disease burden.
In children with pneumonia, blood pneumococcal PCR
(based on pneumolysin) was positive in 100% of children with
positive blood cultures and in only 5% of healthy controls [2].
The Binax NOW (Binax, Portland, ME, USA) Streptococcus
pneumoniae antigen test is a rapid assay for the qualitative
detection of S. pneumoniae antigen in the urine of patients with
pneumonia and detects C-polysaccharide antigen. In children
with pneumonia, Binax NOW has been shown to have a
sensitivity and speciﬁcity of 87% and 63%, respectively, for
diagnosis of pneumococcal pneumonia, but pneumococcal an-
tigen was also detected in 43% of urine samples from healthy
nasopharyngeal S. pneumoniae carriers [3]. Binax NOW has
been associated with false-positive ﬁndings, especially in chil-
dren with high rates of nasopharyngeal pneumococcal coloni-
zation [4–6].European Society of Clinical Microbiology and Infectious Diseases
.0/)
TABLE 1. Binax NOW and pneumococcal PCR positivity in
NMNI Lees et al. Comparison of antigen test and DNA assay 5Patients and methods
children with and without pneumococcal carriage
Test No carriage Carriage p
Binax NOW 21/68 (30.9%) 22/50 (44%) NS
Pneumococcal PCR 28/65 (43.1%) 43/50 (82%) <0.0005
Total 68 50
Pneumococcal PCR was not performed in three patients.We aimed to compare the performance of Binax NOW urine
antigen test and a real-time blood PCR assay in healthy Mala-
wian children with pneumococcal nasopharyngeal carriage
before and after nasopharyngeal swabbing (NPS). The study was
conducted at Queen Elizabeth Central Hospital in Blantyre,
Malawi. Between April 2004 and April 2006, children who
presented with meningitis and pneumonia were recruited as
cases into a study examining genetic susceptibility to IPD, and
healthy asymptomatic children from the same villages served as
controls [7]. A control was a healthy, afebrile, malaria apar-
asitaemic child from the same village as the case. For each index
case, at least three healthy, age-matched children were selected
from the neighborhood. Pneumococcal conjugate vaccine had
not yet been introduced into Malawi when the study was
conducted. NPS, urine sample for Binax NOW antigen testing
and a ﬁnger-prick blood sample for pneumococcal PCR and
malaria parasites were collected. NPS samples were collected in
STGG medium and cultured within 4 hours on sheep’s blood
and chocolate agar, and presumptive S. pneumoniae colonies
were identiﬁed on the basis of their morphology and Optochin
sensitivity. Pneumococcal carriage was deﬁned as growth of
S. pneumoniae on culture from a NPS. Binax NOW urine an-
tigen testing was performed according to the manufacturer’s
instructions. Pneumococcal bacterial DNA (pneumolysin) was
ampliﬁed and quantiﬁed using real-time PCR as previously
described [8,9]. Brieﬂy, this is a single-tube multiplex PCR assay
which was developed based on N. meningitidis, S. pneumoniae
and H. inﬂuenzae targets. The pneumococcal PCR component is
speciﬁc for 23 pneumococcal serotypes while simultaneously
offering a high level of sensitivity. In this study, a cutoff value of
100 copies/mL was used a priori to deﬁne a positive pneumo-
coccal PCR test. This cutoff was chosen on the basis of previous
literature. The plasma ply PCR used by Abdeldaim et al. [10]
reported that all positive samples had copy numbers >103/
mL. The study was approved by the University of Malawi
College of Medicine research ethics committee.Results
TABLE 2. Binax NOW and pneumococcal PCR positivity in






Binax NOW positive 35/88 (39.8%) 8/30 (26.7%) >0.05
Pneumococcal PCR
positive
66/88 (75%) 5/27 (18.5%) <0.0005
Total 88 30
Pneumococcal PCR was not performed in three patients.We recruited 118 healthy, asymptomatic children, of whom 8/
118 (6.8%)wereHIV infected. Therewere 63 boys (53.4%)with a
median age of 5.9 years (interquartile range (IQR), 3.8–8.3 years).
Pneumococcal carriage rate was 42.4% (50/118). Overall, Binax
NOW was positive in 22/51 (44%) children with pneumococcal
carriage and 21/68 (30.9%) without carriage (p > 0.05) (Table 1).
In the ﬁrst 88 children,NPSwas performed before blood samplingNew Microbes and New Infections © 2015 The Authors. Published by Elsevier Ltd on b
This is an oas a result of concerns that the children might become upset after
blood sampling and refuse NPS. When the swabs were done
before the blood sampling was performed for pneumococcal
PCR, 66/88 (75%) children had a positive pneumococcal blood
PCR, with a median pneumococcal bacterial load of 2040 copies/
mL (range, 113–511 518 copies/mL; IQR, 464–15842 copies/
mL). The Bacterial load was higher in children in whom NPS was
performed before blood sampling, but this difference was no
longer signiﬁcant after adjusting for age and HIV status (Table 2).
When swabbing was performed ﬁrst, 22/50 (44%) children with
pneumococcal carriage had a positive BinaxNOWtest compared
with 13/38 (34%) without pneumococcal carriage (p > 0.05).
Following these results, we speculated that NPS was inducing
a transient pneumococcal DNAaemia, so we performed blood
sampling for pneumococcal PCR before NPS in the remaining
children. When blood sampling was performed ﬁrst, 5/27 (18%)
had a positive pneumococcal PCR, with a median bacteria load
of 2369 copies/mL (range, 1996–263 597 copies/mL; IQR,
2101–134 114 copies/mL). When blood tests were taken ﬁrst,
8/30 (27%) without pneumococcal carriage had a positive Binax
NOW result. (None of these children had pneumococcal
carriage.)DiscussionOur data are consistent with previous studies suggesting that
Binax NOW has a high false-positive rate in asymptomaticehalf of European Society of Clinical Microbiology and Infectious Diseases, NMNI, 8, 4–6
pen access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)
6 New Microbes and New Infections, Volume 8 Number C, November 2015 NMNIchildren colonized with S. pneumoniae. The high false-positive
rate even in those without pneumococcal carriage suggests
that our carriage detection rate was an underestimate.
Interestingly, our results suggest that NPS can induce a
signiﬁcant pneumococcal DNAaemia; this warrants further
study. Assessment of pneumococcal bacterial load should be
performed before NPS to avoid artifactual increases in bac-
terial load; however, pneumococcal DNAaemia also
occurred in healthy colonized children before NPS. We
speculate that the process of NPS may be creating some sort
of friction on the mucosal membrane, altering the integrity of
the epithelial barrier and allowing invasion into the
bloodstream.
PCR-based assays for identifying S. pneumoniae targeting
pneumolysin (ply) should ideally, be speciﬁc for S. pneumoniae.
However, viridans group streptococci (S. mitis or S. oralis)
have been reported to occasionally harbour genes encoding
S. pneumoniae virulence factors [11]. Nonetheless, in our
study, when the same assay was performed before NPS, the
positivity rate was signiﬁcantly lower. Pneumolysin PCR has
been reported to be not speciﬁc enough for routine use with
small plasma volumes for the detection of nonbacteraemic
pneumococcal pneumonia; however, our assay uses whole
blood, not plasma. We previously showed that the sensitivity
of a meningococcal PCR for conﬁrming clinical meningococcal
disease improved signiﬁcantly with a new whole-blood Taq-
Man PCR compared to a serum TaqMan PCR method. Lack of
speciﬁcity is also seen with the pneumococcal lytA PCR assay.
Although current practice in our laboratory is to routinely
run both ply and lytA assays for conﬁrmation of positive
pneumococcal PCR, at the time of our study, only ply was
used. Our data highlight the challenges and limitations of using
ply-based PCR assays for the diagnosis of IPD in resource-
poor settings where there is a high prevalence of
pneumococcal carriage in children. Larger studies are
required to assess the performance of different pneumococcal
PCR assays in healthy controls with and without pneumo-
coccal carriage.Conﬂict of interestNone declared.New Microbes and New Infections © 2015 The Authors. Published by Elsevier Ltd on behalf of
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